At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
MDT-4107 Drug Eluting Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries
In Brief
A clinical study evaluating MDT-4107 Drug Eluting Stent for Arterial Occlusive Diseases and 3 related conditions. Completed, enrolled 100 participants across 14 sites.
Detailed Summary
The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent for the treatment of de novo lesions in native coronary arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArterial Occlusive Diseases, Myocardial Ischemia, Cardiovascular Diseases, Coronary Artery Disease
CountriesJapan
CollaboratorsMedtronic Japan Co., Ltd.
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedJun 2009
Primary CompletionDec 2010
Study CompletionFeb 2015
TodayJul 2026
First PostedJun 25, 2009
Enrollment StartMar 1, 2009
Primary CompletionDec 1, 2010
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.0 years ago
Interventions
MDT-4107 Drug Eluting Stentdevice
Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent